Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ACRS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| A-101 Topical Solution | Seborrheic Keratosis | Phase 4 · NCT03487588 | Completed |
| Active | Common Wart | Phase 3 · NCT03691831 | Completed |
| ATI-502 | Atopic Dermatitis | Phase 2 · NCT03585296 | Completed |
| Zunsemetinib (ATI-450) | Rheumatoid Arthritis | Phase 2 · NCT05279417 | Completed |
| ATI-50002 | Androgenetic Alopecia | Phase 2 · NCT03495817 | Completed |
| ATI-50002 topical solution | Vitiligo | Phase 2 · NCT03468855 | Completed |
| ATI-501 400mg BID (Low dose) | Alopecia | Phase 2 · NCT03594227 | Completed |
| ATI-2138 | Atopic Dermatitis | Phase 2 · NCT06585202 | Completed |
| ATI 502 0.46% Topical Solution | Alopecia Areata | Phase 2 · NCT03759340 | Terminated |
| ATI-045 | Atopic Dermatitis | Phase 2 · NCT07011706 | Active not recruiting |
| ATI-1777 | Atopic Dermatitis | Phase 2 · NCT04598269 | Completed |
| ATI-1777 0.5% w/w | Atopic Dermatitis | Phase 2 · NCT05432596 | Completed |
| ATI-1777 1.0% w/w | Atopic Dermatitis | Phase 2 · NCT05432596 | Completed |
| ATI-1777 2.0% w/w | Atopic Dermatitis | Phase 2 · NCT05432596 | Completed |
| mFOLFIRINOX | Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 · NCT06648434 | Recruiting |
| MK2 Inhibitor ATI-2231 | Advanced Solid Tumor | Phase 1 · NCT05791474 | Withdrawn |
Also used in these trials (approved or third-party drugs, not ACRS's own candidates): Oxymetazoline Hydrochloride, Capecitabine, Denosumab, Methotrexate, Zoledronic Acid.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ACRS holds $170.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $19M/quarter from operations, an estimated runway of 26.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 39 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACRS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Braden Michael Leonard 10% owner |
Insider | 13,950,000 | 9.48% | 2026-04-27 |
| BML Investment Partners, L.P. | 5%+ holder (13G) | 13,950,000 | 9.48% | 2026-04-23 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 12,723,026 | 8.64% | 2026-06-30 |
| Biosion, Inc. | 5%+ holder (13G) | 11,281,950 | 7.66% | 2025-12-09 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 9,345,000 | 6.35% | 2026-03-09 |
| Frazier Life Sciences Public Fund, L.P. | 5%+ holder (13G) | 7,879,943 | 5.35% | 2026-09-14 |
| BlackRock, Inc. | Institution (13G, 5%+) | 6,700,629 | 4.55% | 2025-12-31 |
| Neal Walker CEO, Director · +1.15M options |
Insider | 1,543,886 | 1.05% | 2026-02-03 |
| Anand Mehra Director · +84,700 options |
Insider | 726,403 | 0.49% | 2026-06-04 |
| Andrew N Schiff Director · +84,700 options |
Insider | 459,995 | 0.31% | 2026-06-04 |
| James Loerop Chief Business Officer · +412,025 options |
Insider | 192,260 | 0.13% | 2026-02-03 |
| Kevin Balthaser Chief Financial Officer · +346,800 options |
Insider | 187,453 | 0.13% | 2026-03-01 |
Share count 147,198,893 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACRS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →